ArticleTheranostics2023

Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency.

Wenyan Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.